EWTX Stock — Edgewise Therapeutics Inc.: Cash, EV, Pipeline

Share price

$45.32

Market cap

$4,921.9M

Cash

$460.7M

Enterprise value

$4,461.2M

Balance sheet

Cash	$460.7M
Debt	$0.0M
Net cash	$460.7M
Enterprise value	$4,461.2M
Basic shares	107.8M shares
Fully diluted shares	131.6M shares
Fully diluted market cap	$5,966.3M
Cash per share	$4.27

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading EWTX daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Oct 13 - Nov 24	Sevasemten 10 mg	Phase 2	Becker Muscular Dystrophy	—
Feb 12 - Mar 26	Sevasemten Dose 1	Phase 2	Duchenne Muscular Dystrophy	—
Apr 12 - May 24	Sevasemten Dose 1	Phase 2	Duchenne Muscular Dystrophy	—
Jan 12 - Feb 23	EDG-7500	Phase 2	Hypertrophic Cardiomyopathy	—
Jan 12 - Feb 23	EDG-15400 25 mg	Phase 2	Heart Failure With Preserved Ejection Fraction	—
Mar 15 - Apr 26	Sevasemten	Phase 2	Becker Muscular Dystrophy	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

EDG-7500

Phase 2 · Active Modality: small molecule

Target cardiac sarcomere modulator (CSM)

Indications

Hypertrophic cardiomyopathy (obstructive and nonobstructive HCM) (Phase 2)

Status note Lead cardiovascular program. Multipart Phase 2 CIRRUS-HCM trial in oHCM and nHCM; topline reported June 2026. Company is now cardiovascular-focused after selling sevasemten to Servier (July 2026).

EDG-15400

Phase 1 · Active Modality: small molecule

Target cardiac sarcomere modulator (CSM)

Indications

Heart failure with preserved ejection fraction (HFpEF) (Phase 1)

Status note Second cardiac sarcomere modulator; Phase 1 in healthy adults (dosing completed); future disease target HFpEF.

Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Sevasemten Dose 1
Lead indication	Duchenne Muscular Dystrophy
Lead phase	Phase 2
Active trials	6
Collaborator trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT05540860	Phase 2	Active, not recruiting	Sponsor	EWTX	—	Duchenne Muscular Dystrophy	—
NCT06100887	Phase 2	Active, not recruiting	Sponsor	EWTX	—	Duchenne Muscular Dystrophy	—
NCT06347159	Phase 2	Active, not recruiting	Sponsor	EWTX	—	Hypertrophic Cardiomyopathy	—
NCT07795814	Phase 2	Recruiting	Sponsor	EWTX	—	Heart Failure With Preserved Ejection Fraction	—
NCT06066580	Phase 2	Enrolling by invitation	Sponsor	EWTX	—	Becker Muscular Dystrophy	—
NCT05291091	Phase 2	Active, not recruiting	Sponsor	EWTX	—	Becker Muscular Dystrophy	—
NCT05257473	Not disclosed	Active, not recruiting	Collaborator	Virginia Commonwealth University	—	Becker Muscular Dystrophy; Muscular Dystrophies; Muscular Dystrophy in Children	—

Sponsor-matched active trials from ClinicalTrials.gov (6 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 7 active trials for Edgewise Therapeutics, Inc. on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
OrbiMed Advisors	15,518,492	no change	11.94%	2026-08-14
Baker Bros. Advisors	3,701,719	-2,874,221	0.75%	2026-08-14
Braidwell LP	1,996,965	-350,618	3.00%	2026-08-14
ADAR1 Capital Management	143,199	+52,600	0.27%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

EWTX — Edgewise Therapeutics Inc.